+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastroparesis Market Insights, Epidemiology, and Market Forecast - 2028

  • ID: 4871932
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 193 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Allergan
  • ANI Pharmaceuticals
  • Bird Rock Bio
  • Censa Pharmaceuticals
  • CinDome Pharma
  • Evoke Pharma
  • MORE
‘Gastroparesis Market Insights, Epidemiology, and Market Forecast - 2028' report deliver an in - depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017 - 2028

Gastroparesis - Disease Understanding and Treatment Algorithm

Gastroparesis, which is a translated meaning of “stomach paralysis”, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia, makes the diagnosis of Gastroparesis difficult.

According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.

The etiology of Gastroparesis include diabetic, postsurgical, Iatrogenic, surgical and idiopathic as these are major causes of gastroparesis. Based on the causes, Gastroparesis is divided into three major types, i.e., Idiopathic gastroparesis, Diabetic gastroparesis, and Post - surgical gastroparesis. Some of the researchers proposed a classification system to help determine appropriate treatment options such as Grade 1, or mild gastroparesis, is characterized by symptoms that come and go and can easily be controlled by dietary modification and by avoiding medications that slow gastric emptying. Grade 2, or compensated gastroparesis, is characterized by moderately severe symptoms. Individuals with Grade 2 Gastroparesis are treated with medications that stimulate gastric emptying and medications that reduce vomiting; such individuals require hospitalization only infrequently. Grade 3, or gastric failure, is characterized by individuals who do not respond to medications used to treat gastroparesis. These individuals cannot maintain proper nutrition or hydration. Required therapies may include intravenous fluids and medications and nutrition, or surgery. Individuals with Grade 3 Gastroparesis often require hospitalization.

The treatment of Gastroparesis is based on the severity of symptoms of the disease. If diabetes is associated with gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of Gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.

Gastroparesis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender - Specific Prevalence of Gastroparesis, Severity - Specific Prevalence of Gastroparesis, Type - Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

This analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. In addition to this, it was accessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017.

Gastroparesis Drug Chapters

Gastroparesis is a complex, debilitating dysmotility disorder with challenging symptom management. Given the limited efficacy of treatment options and serious side effects, significant research continues for therapeutic options for Gastroparesis.

The treatment landscape of Gastroparesis comprises of very few pharmacotherapies. The usual treatments for Gastroparesis include nutritional assessment, dietary modifications, and Pharmacological Therapies. Pharmacological therapies include Prokinetic Agents, Antiemetic Agents (off - label), and Antianxiety Benzodiazepine Agents (off - label). Apart from these Pharmacological therapies, Electrical Stimulation Therapies, Endoscopic Therapies, and Surgical Therapies are used for the treatment management of Gastroparesis. The primary aim of present therapies is to improve the efficiency of the gastric pump and to relieve symptoms of nausea, bloating, vomiting, and pain. The selection of recommended drugs is based on the severity of the symptoms (grades).

“According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Metoclopramide, Domperidone, Erythromycin, Antiemetics, Antidepressants, and Pain medicines are helpful for the treatment of Gastroparesis and associated symptoms.”

Gastroparesis Market Outlook

The market size of Gastroparesis in seven major markets (7MM) is estimated to be USD 3,414.16 million in 2017. The United States accounts for the highest market size of Gastroparesis,i.e. USD 1,558.41 million, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while the UK had the lowest market size of Gastroparesis in 2017.

Gastroparesis Drugs Uptake

With the launch of emerging therapies like Gimoti (EVK - 001, a product of Evoke Pharma), which is a metoclopramide nasal spray, Relamorelin (Allergan), Tradipitant (Vanda Pharmaceuticals), Velusetrag (Theravance Biopharma), and CIN - 102 (Deuterated Domperidone, CinRX Pharma), the market of Gastroparesis is anticipated to change during the forecast period (2019 - 2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above - mentioned drug candidates have shown very promising results and it has been anticipated by the publisher's analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of Gastroparesis will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019 - 2028], and with their anticipated launch, the market size of Gastroparesis will also experience significant growth.

Gastroparesis Report Insights
  • Total Prevalence of Gastroparesis
  • Gender - Specific Prevalence of Gastroparesis
  • Severity - Specific Prevalence of Gastroparesis
  • Type - Specific Prevalence of Gastroparesis
  • Total Diagnosed Prevalent Population of Gastroparesis
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Gastroparesis Report Key Strengths
  • 10 - Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Gastroparesis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Gastroparesis market
  • Organize sales and marketing efforts by identifying the best opportunities for Gastroparesis market
  • To understand the future market competition in the Gastroparesis market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan
  • ANI Pharmaceuticals
  • Bird Rock Bio
  • Censa Pharmaceuticals
  • CinDome Pharma
  • Evoke Pharma
  • MORE
1. Key Insights

2. Gastroparesis: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
2.2. Total Market Share (%) Distribution of Gastroparesis in 2028

3. Gastroparesis: Disease Background and Overview
3.1. Introduction
3.2. Types of Gastroparesis: Based on Causes
3.2.1. Idiopathic Gastroparesis (IG)
3.2.2. Diabetic Gastroparesis (DGp)
3.2.3. Iatrogenic and Postsurgical Gastroparesis
3.3. Clinical Signs and Symptoms
3.4. Mechanisms or Pathophysiology of Gastroparesis
3.5. Diagnosis of Gastroparesis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalence of Gastroparesis in the 7MM
4.3. Type-Specific Prevalence of Gastroparesis in the 7MM
4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM
4.5. Severity Specific Prevalence of Gastroparesis in the 7MM
4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalence of Gastroparesis in the United States
5.3. Type-Specific Diagnosed Prevalence of Gastroparesis in the United States
5.4. Gender-Specific Prevalence of Gastroparesis in the United States
5.5. Severity Specific Prevalence of Gastroparesis in the United States
5.6. Total Diagnosed Prevalence of Gastroparesis in the United States

6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Total Prevalence of Gastroparesis in Germany
6.1.2. Type-Specific Prevalence of Gastroparesis in Germany
6.1.3. Gender-Specific Prevalence of Gastroparesis in Germany
6.1.4. Severity Specific Prevalence of Gastroparesis in Germany
6.1.5. Total Diagnosed Prevalence of Gastroparesis in Germany
6.2. France Epidemiology
6.2.1. Total Prevalence of Gastroparesis in France
6.2.2. Type-Specific Prevalence of Gastroparesis in France
6.2.3. Gender-Specific Prevalence of Gastroparesis in France
6.2.4. Severity Specific Prevalence of Gastroparesis in France
6.2.5. Total Diagnosed Prevalence of Gastroparesis in France
6.3. Italy Epidemiology
6.3.1. Total Prevalence of Gastroparesis in Italy
6.3.2. Type-Specific Prevalence of Gastroparesis in Italy
6.3.3. Gender-Specific Prevalence of Gastroparesis in Italy
6.3.4. Severity Specific Prevalence of Gastroparesis in Italy
6.3.5. Total Diagnosed Prevalence of Gastroparesis in Italy
6.4. Spain Epidemiology
6.4.1. Total Prevalence of Gastroparesis in Spain
6.4.2. Type-Specific Prevalence of Gastroparesis in Spain
6.4.3. Gender-Specific Prevalence of Gastroparesis in Spain
6.4.4. Severity Specific Prevalence of Gastroparesis in Spain
6.4.5. Total Diagnosed Prevalence of Gastroparesis in Spain
6.5. United Kingdom Epidemiology
6.5.1. Total Prevalence of Gastroparesis in the United Kingdom
6.5.2. Type-Specific Prevalence of Gastroparesis in the United Kingdom
6.5.3. Gender-Specific Prevalence of Gastroparesis in the United Kingdom
6.5.4. Severity Specific Prevalence of Gastroparesis in the United Kingdom
6.5.5. Total Diagnosed Prevalence of Gastroparesis in the United Kingdom

7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalence of Gastroparesis in Japan
7.3. Type-Specific Prevalence of Gastroparesis in Japan
7.4. Gender-Specific Prevalence of Gastroparesis in Japan
7.5. Severity Specific Prevalence of Gastroparesis in Japan
7.6. Total Diagnosed Prevalence of Gastroparesis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Treatment Algorithm for Gastroparesis
8.2. Treatment and Management for Gastroparesis
8.2.1. Dietary Modifications
8.2.2. Pharmacological Treatment
8.2.3. Pyloric Intervention
8.2.4. Gastric Electrical Stimulation

9. Proposed Clinical Guidelines for the Management of Gastroparesis
9.1. Recommendations
9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Products
11.1. Reglan: ANI Pharmaceuticals
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Product Profile
11.2. Motilium (Domperidone): Janssen
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Safety and Efficacy
11.2.4. Product Profile

12. Emerging Therapies
12.1. Key Cross Competition
12.2. Relamorelin: Allergan
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Product Profile
12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Tradipitant: Vanda Pharmaceuticals
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
12.5. Velusetrag: Theravance Biopharma
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. CNSA-001: Censa Pharmaceuticals
12.6.1. Product Description
12.6.2. Clinical Development
12.6.3. Product Profile
12.7. Nimacimab: Bird Rock Bio
12.7.1. Product Description
12.7.2. Other Development Activities
12.7.3. Clinical Development
12.7.4. Product Profile
12.8. CIN-102: CinDome Pharma
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. TAK 906: Takeda (Millennium Pharmaceuticals)
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.9.4. Safety and Efficacy
12.9.5. Product Profile

13. Gastroparesis: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Gastroparesis in 7MM
13.3. Market Size of Gastroparesis by Therapies in the 7MM

14. United States: Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of Gastroparesis in the United States
14.1.2. Market Size of Gastroparesis by Therapies in the US

15. EU-5 countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of Gastroparesis in Germany
15.1.2. Market Size of Gastroparesis by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of Gastroparesis in France
15.2.2. Market Size of Gastroparesis by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of Gastroparesis in Italy
15.3.2. Market Size of Gastroparesis by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of Gastroparesis in Spain
15.4.2. Market Size of Gastroparesis by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of Gastroparesis in the United Kingdom
15.5.2. Market Size of Gastroparesis by therapies in the UK

16. Japan Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of Gastroparesis in Japan
16.1.2. Market Size of Gastroparesis by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix
19.1. Report Methodology

20. Publisher Capabilities

21. Disclaimer

22. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • CinDome Pharma
  • Takeda (Millennium Pharmaceuticals)
  • Evoke Pharma
  • Vanda Pharmaceuticals
  • Theravance Biopharma
  • ANI Pharmaceuticals
  • Janssen
  • Allergan
  • Censa Pharmaceuticals
  • Bird Rock Bio
Note: Product cover images may vary from those shown
Adroll
adroll